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Summary Coronary heart disease is a common and serious condition in patients aged over
80 years. The presenting clinical symptoms are all the more atypical and the prognosis poorer
when it occurs in patients with multiple comorbid diseases. The presence of comorbidities dic-
tates the need for a standardized geriatric assessment to screen for the existence of underlying
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frailty. The available scientiﬁc data were obtained during studies that included few sub-
jects aged over 80 years. These recommendations are therefore mainly extrapolated from
results obtained in younger populations. The pharmacological management and revascular-
ization strategy for coronary heart disease in octogenarians is basically the same as in younger
subjects. Epidemiological studies all concur that available therapies are underutilized despite
the fact that this population has a high cardiovascular risk. Speciﬁc precautions for use must be
respected because of the comorbidities and age-related changes in pharmacokinetics or phar-
macodynamics. Generally, the therapeutic strategy in coronary heart disease is based not on
the patient’s real age, but rather on an individual analysis taking into account the severity of
the coronary disease, comorbidities, the risk of drug misadventures, patient life expectancy
and quality of life.
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ortality due to ischaemic heart disease fell by 16% in France
etween 1988—1990 and 1995—1997, but this condition still
auses 27% of deaths from cardiovascular disease. This mor-
ality increases with age and is always higher in men [1].
early one-third [2—4] of patients admitted for myocardial
nfarction are over 75 years old and represent nearly 50% of
ospital mortality due to this disease. Patients over 85 years
ave six times more cardiogenic shocks, three times more
trokes, twice as many major bleeding events and three to
ine times higher mortality [5,6].
Few data are available in the literature about coronary
nsufﬁciency in adults aged over 80 years. Old age is an
xclusion criterion in most randomized controlled trials on
CS. This article, compiled from a review of the literature,
s an ‘expert consensus’ of the French Societies of cardi-
logy and geriatrics/gerontology on the speciﬁc features of
anagement of coronary heart disease in patients aged over
0.
linical approach
he presentation of coronary insufﬁciency in the older sub-
ect often differs from that in younger adults and atypical
linical features are often observed.
ngina pain
ngina pain remains the most frequent inaugural sign of
oronary insufﬁciency in the elderly, although it has a lower
ncidence than in younger adults. It may be more difﬁ-
ult to analyse because of communication difﬁculties and
n particular the presence of cognitive impairment, which
ay cause patients to ‘forget’ symptoms. Atypical patho-
ogical features are frequent in older adults, particularly in
omen: gastrointestinal disorders, asthenia and deteriora-
ion in general health status may be the main presenting
ymptoms. Ischaemic heart disease may also lead to blockp-
ea, acute pulmonary oedema, rhythm disorders or even
udden death [7].ilent ischaemia
ilent ischaemia is more frequent in the elderly [8] because
f impaired sensory nerve function, deterioration in corti-
al function or dysautonomia. Coronary heart disease may
T
a
p
c
ae asymptomatic when physical activity is reduced below
he ischaemic threshold by a sedentary lifestyle or loco-
otor disability. The incidence of confounding diseases [9]
spondylosis or shoulder osteoarthritis, chest wall pain or
astrointestinal diseases) makes clinical analysis more difﬁ-
ult.
yocardial infarction
iagnosis of myocardial infarction may also be difﬁcult in
lder adults and the presenting symptom may be a compli-
ation (acute pulmonary oedema, stroke, acute ischaemia
f the lower limbs, heart rhythm disorder or sudden death)
r a gastrointestinal or neurological symptom (confusional
yndrome, behavioural disorders, syncope or vertigo or even
imple headaches [10]). Atypical symptoms often lead to
elays in treatment [11].
linical examination
he clinical examination determines the distribution of the
theromatous disease (arterial murmur, detection of abdom-
nal aortic aneurysm). The physical examination may also
eveal arrhythmia or signs of heart failure. A measurement
f seated and then standing blood pressure is indicated (to
est for orthostatic hypotension, deﬁned as a fall of 20mmHg
n systolic blood pressure and/or 10 mmHg in diastolic blood
ressure). Finally, a precise neurological examination should
e performed. This should be completed by a SCGA.
eriatric approach
he management of older adults with coronary insufﬁ-
iency has different objectives depending on the patient.
n autonomous elderly subjects with no severe concomi-
ant disease, it is identical to that of younger adults. The
im of management of a dependent older adult with mul-
iple comorbid diseases is to preserve vital functions while
voiding adverse drug reactions.
lobal assessmenthis essential assessment is often difﬁcult to perform in
n emergency setting and must be completed when the
atient’s condition has stabilized, where necessary by a spe-
ialized team. It assesses medical and psychosocial items
nd uses simple tests for the rapid detection of concomitant
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diseases, an evaluation of the patient’s autonomy and
his/her social conditions. The SCGA makes it possible to
evaluate frailty characterized by a reduction in physiological
capacities to adapt to stress or changes in the environment
associated or not with organ failure. The main items of the
SCGA are the following.
Evaluation of cognition
The MMSE (Folstein’s MMSE [12]), scored out of 30, consti-
tutes a simple, rapid and standardized test for detecting
cognitive impairment (Appendix 1) [13]. The threshold value
depends on the patient’s age and sociocultural level. A score
over 27 is considered to be normal. A score below 24 is
abnormal and dictates the need for a detailed assessment of
cognitive function in a specialized unit. A score of between
24 and 27 should be considered abnormal for patients who
are not extremely old (< 80 years), with a high sociocultural
level and who have disturbances of memory or other cog-
nitive functions. An abnormal MMSE score shows cognitive
dysfunction not necessarily related to dementia. An abnor-
mal score therefore calls for specialized evaluation and is
not sufﬁcient in itself to establish diagnosis.
Evaluation of dependence
Evaluation of dependence speciﬁes limitations that may hin-
der complementary investigations, worsen prognosis [14]
and impact the therapeutic approach. Dependence may be
assessed with Activities of Daily Living scales (IADL or ADL) by
interviewing the patient and his/her close contacts. There
is a shortened four-item form of the IADL [15] based on:
use of the telephone, means of transport, medication use
and management of money (Appendix 2). The ADL scale pro-
vides information about personal hygiene, dressing, use of
toilets, transferring, urine and bowel continence and eat-
ing. The subject is considered to be dependent as soon as
he/she needs human help to carry out the activity concerned
(Appendix 3) [16].
Somatic geriatric evaluation
This takes into account the evaluation of gait disorders and
the risk of falling (unipedal stance test to evaluate the
capacity to stand on one leg for 5 seconds). Likewise, nutri-
tional status is assessed using validated scales (MNA scale)
for the assay of plasma albumin or prealbumin [17]. Body
weight must be interpreted after taking into account possi-
ble malnutrition and any ﬂuid retention or dehydration.
Psychological evaluation
Depression is very frequent in older adults and may impact
the manifestations of coronary disease and its treatment.
It represents an independent risk factor for cardiovascular
mortality [18]. Its detection and management are there-
fore essential in older adults. The simpliﬁed GDS provides
an initial assessment (Appendix 4).Evaluation of life circumstances
The purpose of this evaluation is to:
• estimate adherence to the proposed treatment. If the
patient cannot manage his/her own treatment, it must be
d
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determined how (preparation, use of a tablet container)
and by whom (family, domestic assistant, carer, nurse) it
will be administered;
specify the procedures for preparing food and meals;
evaluate the patient’s state of isolation and his/her access
to different care services.
ommunity health management
t is important to evaluate the patient’s social condition and
ake into account the role of caregivers (family relations or
riends). This management involves informing and educat-
ng the patient’s close contacts about the disease to make
ure that he/she takes the medication and permit rapid
etection of any change in symptoms and thresholds for the
riggering of symptoms. This may require implementation
f a home-help system. Different types of care and sup-
ort are available including help to ensure personal hygiene
rom a nurse or nursing auxiliary, supply of medications
nurse), meals-on-wheels, domestic help (home helper) or
are-giving (carer).
Depending on the SCGA data, the patient may be seen by
geriatrician in order to organize management and appro-
riate follow-up. Such management of the frail elderly has
een shown to result in a signiﬁcant reduction in mortality
nd admission to institutions [19].
dditional diagnostic and prognostic
nvestigations
lectrocardiogram (ECG)
he ECG is rarely normal at baseline in older persons with
oronary disease. Interpretation of repolarization is often
indered by the presence of left ventricular hypertrophy,
lectrical sequelae of infarction, a left bundle branch block,
lectrosystolic pacing, treatment by digitalis preparations
r electrolyte disorders. The resting ECG may, however, be
ormal [20]. In this case, repeated recordings at short inter-
als and clinical and laboratory examinations should improve
iagnosis. The ECG also provides prognostic information. For
nstance, the risk of coronary events is raised in the case of
T-segment depression greater than 1mm [21].
xercise ECG
n exercise ECG may rarely be performed in older adults
ho often have mobility disorders, joint pain, physical
econditioning and concomitant neurological, vascular or
espiratory disorders [22]. No study of the sensitivity and
peciﬁcity of the exercise test has been performed in the
ery elderly. Those evaluating its prognostic value gave con-
radictory results [23,24].
yocardial perfusion scintigraphy
yocardial perfusion scintigraphy, at rest or after dipyri-
amole or dobutamine stress, has a good sensitivity and
peciﬁcity in subjects aged over 80 years for the detection
f signiﬁcant coronary stenosis [25] and the evaluation of
he prognosis [26], although this examination is not always
vailable.
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tress echocardiography
tress echocardiography may also be proposed in the elderly.
hysical exercise may be used as stress factor although phar-
acological stress testing is more often performed because
f functional limitations. The sensitivity and speciﬁcity of
xertional echocardiography are similar to those in popula-
ions of younger patients [27]. After 75 years, dobutamine
tress echocardiography is accompanied by an increased
ncidence of hypotension and ventricular arrhythmia [28].
ther evaluation procedures
he role of coronary computed tomography angiography and
agnetic resonance imaging in the diagnosis of the coronary
nsufﬁciency is undergoing evaluation in older adults in par-
icular, because of the renal risks related to iodine injection
equired for the computed tomography scan.
ther complementary examinations
ssays of blood glucose levels and a lipid assessment are
seful for the evaluation of cardiovascular risk. Serum
reatinine concentrations and creatinine clearance calcu-
ated with the Cockcroft-Gault formula are used to assess
enal function. Impaired renal function, in particular when
evere (clearance < 30mL/min), is a factor of poor progno-
is, increasing the risk of adverse drug events especially if
oronary angiography is performed. Rehydration is essential
efore conducting this examination, as soon as the clearance
s less than 60mL/min.
arkers of ischaemia and myocardial necrosis
ssay of biomarkers of myocardial ischaemia (creatinine
hosphokinase, troponin) contribute to the diagnosis and
rognosis for patients with ACS. The procedures for using
nd interpreting the results of these assays are not affected
y age, although the presence of macro creatine kinases,
eading to false positives, is more frequent in elderly women
29]. In the case of severe renal insufﬁciency, a slight rise in
roponin T may occur outside any ACS [30].
oronary angiography
oronary angiography is the reference diagnostic exam-
nation for the detection of coronary lesions. It has a
igher morbidity and mortality rate in octogenarians. The
ndication for coronary angiography must therefore be
stablished after evaluating the patient’s conditions, mainly
ith respect to possible revascularization.
edical treatment of ACS in the older
ubject
eﬁnitionCS [31] in older adults comprises:
ST-segment elevation ACS: prolonged suggestive chest
pain (> 20 minutes’ duration) accompanied by persistent
ST-segment elevation (or new left bundle branch block);
a
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increase in cardiac biomarkers (in particular troponin I or
T) [32];
non-ST-segment elevation ACS: prolonged suggestive
chest pain or chest pain of recent onset (de novo
angina) or worsening of angina generally accompanied
by electrical modiﬁcations without persistent ST-segment
elevation; increase in cardiac biomarkers (in particular
troponin I or T) [33,34].
ack of ‘evidence-based’ data
lder adults are under-represented in the main studies in
CS. More than half of the trials conducted between 1996
nd 2000 included no patient aged over 75 years [28]. It is not
herefore known if the algorithms and guidelines established
ith cohorts of younger patients are applicable to older
ubjects. Likewise, the best endpoint for use in this popula-
ion with a reduced life expectancy is not known (mortality,
ardiovascular events or quality of life?).
edical management
he different epidemiological studies all underline the
elayed management and under-utilization of medication in
CS. Compared with younger patients, those over 75 years
re less often given beta-blockers, aspirin, clopidogrel,
tatins, thrombolysis (in the case of ST-segment elevation
CS) and glycoprotein IIb/IIIa antagonists [2—4]. Conversely,
lderly subjects often receive more calcium antagonists
nd angiotensin-converting enzyme inhibitors [4], probably
ecause of the increased prevalence of hypertension and
eart failure. Likewise, increased use of LMWHs is observed
espite the increased bleeding risk in this population.
The optimum medical management of older adults with
CS is not very different from that of younger subjects.
owever, the frailty of this population dictates the need for
ncreased rigor in respecting contraindications, careful insti-
ution of the different therapeutic classes and monitoring
or possible side-effects.
latelet-aggregation inhibitors
spirin
he prescription of aspirin is recommended [35,36] from the
cute phase, at a dosage of between 75 and 325mg/day
n the absence of allergy, exacerbation of peptic ulcer or
leeding disorders, and must be continued over the long
erm. Its side-effects (mainly gastrointestinal) are uncom-
on at low doses (75—150mg/day) but must be carefully
ought.
lopidogrel
he prescription of clopidogrel monotherapy is recom-
ended in the case of contraindications to aspirin. The
ombination of clopidogrel with low doses of aspirin has
ot been evaluated in subjects over 80 years. Taking into
ccount the divergent results of the CURE [37] and PCI-CURE
tudies [38] in patients aged over 65 years, dual antiplatelet
herapy may only be recommended on an individual basis
fter taking into account the beneﬁt-to-risk ratio for each
atient.
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The optimum duration of treatment with the
aspirin—clopidogrel combination has not been well
evaluated in older adults, and must take into account
the patient’s general status and/or the implantation of a
drug-eluting stent. There are no data evaluating the beneﬁt
and safety of loading doses in patients over 80 years.
Withdrawal of antiplatelet therapy in older adults
This is frequently necessary because of the multiple comor-
bid diseases in this population. Discontinuation of platelet
aggregation inhibitors is a major risk factor for thrombo-
sis of all coronary stents and in particular late thrombosis
in drug-eluting stents. Recommendations exist about the
management of oral antiplatelet therapy in patients with
coronary stents, in particular in patients requiring surgery,
although these do not speciﬁcally concern elderly patients
[39].
Glycoprotein IIb/IIIa antagonists
Few randomized studies have evaluated the beneﬁt of gly-
coprotein IIb/IIIa antagonists in patients over 75 years. In
patients with ST-segment elevation ACS, they may be used
in primary angioplasty with coronary stenting [29,40] after
careful analysis of the trade-off between beneﬁt and risks,
and ruling out contraindications (stroke, surgery or recent
trauma, coagulation disorders, hepatic insufﬁciency, active
haemorrhage, severe arterial hypertension). On the con-
trary, their prescription, in combination with ﬁbrinolytics,
is clearly contraindicated in patients over 75 years [29].
Subjects over 75 years, admitted for non-ST-segment
elevation ACS also seem to beneﬁt from adjunctive anti-
glycoprotein IIb/IIIa therapy with early revascularization at
the price, however, of increased bleeding [41].
Anticoagulants
Unfractionated heparin
Unfractionated heparin is recommended in ST-segment ele-
vation ACS whatever revascularization procedure is used,
provided there are no immunoallergic or haemorrhagic con-
traindications [42]. In subjects aged over 75 years with
ST-segment elevation ACS undergoing treatment with ﬁb-
rinolysis, unfractionated heparin was better tolerated than
the LMWH enoxaparin in terms of the risk of intracranial
haemorrhage [37]. In these high-risk patients, clinical and
laboratory monitoring should be reinforced for signs of vis-
ceral or cerebral bleeding.
Low molecular weight heparin
LMWHs, in particular enoxaparin, are recommended in
young patients with ACS [43]. After the age of 75 years,
in combination with thrombolysis during the acute phase
of myocardial infarction, a subgroup of the ASSENT-3 study
suggested that LMWH and unfractionated heparin had sim-
ilar beneﬁts in terms of the composite endpoint of death,
in-hospital reinfarction, refractory ischaemia, intracranial
haemorrhage and major bleeding [44]. However, the risk of
intracranial haemorrhage was higher with enoxaparin than
with unfractionated heparin in older adults in ASSENT-3 Plus
[42].
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The advantages of LMWH are their ease of use and the
ower risk of heparin-induced thrombocytopenia compared
ith unfractionated heparin. Conversely, they must be pre-
cribed with caution in patients aged over 75 years because
f their renal elimination. The dosage must be adjusted
ccording to renal function and anti-Xa activity to avoid
ccumulation responsible for haemorrhagic accidents [45].
creatinine clearance less than 30mL/min is an absolute
ontraindication for curative doses whereas a clearance of
etween 30 and 60mL/min is a relative contraindication
with obligatory control of anti-Xa activity). The duration of
nticoagulant treatment ranged from 48 hours to eight days
epending on the studies and the type of revascularization
rocedure which is not codiﬁed in the elderly.
irect antithrombotics and factor Xa inhibitors
lthough they are not currently recommended in elderly
atients with ACS [36], direct thrombin inhibitors appear
romising [46,47]: fondaparinux appears to have a similar
fﬁcacy to that of enoxaparin in patients with non-
T-segment elevation ACS, with a lower bleeding risk,
articularly in older subjects [48]. In ST-segment elevation
CS, although safety was the same, the beneﬁt was not as
arked as in the subgroup of patients undergoing primary
ngioplasty [49].
itamin K antagonists
itamin K antagonists are not part of the treatment arma-
entarium in ACS. They must be stopped where necessary
nd relayed by heparin anticoagulation.
eta-blockers
rrespective of the type of ACS (ST-segment elevation or
on-ST-segment elevation), beta-blockers have clear short-
nd long-term beneﬁts in terms of reducing recurrence
f myocardial infarction and increasing survival. Although
ew studies have included patients over 75 years, the data
btained from meta-analyses and registries show a ben-
ﬁt whatever the patient’s age. They are recommended
or ﬁrst-line treatment [29], in particular in the case of
eft ventricular dysfunction [50] after ruling out all the
sual contraindications, such as decompensated heart fail-
re, asthma and advanced chronic obstructive pulmonary
isease, and severe conduction disorders, which must be
ought with particular care in the elderly.
Close monitoring of blood pressure, heart rate and the
CG are necessary in this setting. Monitoring for the onset
f bradycardia is necessary in the case of concomitant
rescription of acetylcholinesterase inhibitors. Institution of
eta-blockers must be delayed if there are overt signs of
ater and sodium retention. Treatment should be initiated
autiously with gradual up-titration of the dose to a target
esting heart rate of approximately 60 beats per minute.
nhibitors of the renin-angiotensin systemngiotensin-converting enzyme inhibitors
ngiotensin-converting enzyme (ACE) inhibitors are recom-
ended during the ﬁrst 24 hours of onset of ACS if there
re clinical signs of heart failure and/or a deterioration
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n left ventricular systolic function (left ventricular ejec-
ion fraction < 40%) and/or anterior-wall infarction [51,52].
hey are indicated after myocardial infarction in all patients
nd indeﬁnitely, in the absence of contraindications. There
re few data speciﬁc to patients aged over 75 years and
hese concern subgroup analysis [53]. ACE inhibitors should
e initiated cautiously in older adults and the dose gradu-
lly increased according to renal function. In general, the
aily dosage should be reduced by half compared with that
sed in younger patients. Treatment should be initiated
ong after any episode of sodium depletion, starting with
low dosage, which is then gradually up-titrated to the
aximum tolerated dose. At the same time, the continua-
ion or interruption of other therapies such as diuretics,
alcium antagonists and nitrates should be re-evaluated.
rescription of non-steroidal anti-inﬂammatory drugs is con-
raindicated because of the risk of renal insufﬁciency and
yperkalaemia. Blood pressure (seated and standing), renal
unction and blood electrolytes must be monitored carefully
nd very regularly during the ﬁrst months after myocardial
nfarction, and systematically in the case of acute inter-
urrent episodes of fever, diarrhoea, dehydration, vomiting,
tc.
ngiotensin II receptor antagonists (ARAs)
wo trials [54,55] evaluated the role of ARAs in post-
nfarction heart failure, and included a signiﬁcant number
f patients aged over 75 years. The results showed that
RAs had a similar efﬁcacy to ACE inhibitors irrespective of
he patient’s age. Their use is therefore restricted to post-
nfarct patients intolerant to ACE inhibitors and younger
ubjects. They must be instituted at a low dose. Upward
ose titration and monitoring procedures are similar to those
ecommended for ACE inhibitors.
ldosterone antagonists
o signiﬁcant differences in beneﬁt were observed between
ifferent age groups when eplerenone was used post-
nfarction in patients with signs of heart failure or left
entricular dysfunction. The chosen threshold was, however,
articularly low (65 years) [56]. Because of the risk of hyper-
alaemia due to renal function impairment in the elderly,
he trade-off between risks and beneﬁt should be carefully
ssessed and the contraindications respected in the absence
f any speciﬁc study.
tatins
ew scientiﬁc data are available showing the beneﬁt of
tatins administered to ACS patients aged over 75 years.
owever, subgroup studies suggest that their beneﬁcial
ffect is at least the same as that obtained in younger
atients [57]. The target low-density lipoprotein cholesterol
alue and the doses required to reach it have not been
etermined.alcium antagonists
ihydropyridines have not been shown to have any beneﬁt in
atients with an ACS. They should only be prescribed within
h
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T
dO. Hanon et al.
he scope of their recognised indications, such as hyperten-
ion. They are not therefore recommended except in the
peciﬁc case of conﬁrmed coronary spasm.
The use of rate-limiting calcium antagonists (diltiazem,
erapamil) may be considered when beta-blockers are con-
raindicated, with strict monitoring of the heart rate, ECG
nd blood pressure and for the possible onset of signs of
eart failure.
itrates
itrates have not been shown to improve outcomes in
atients with ACS [58,59]. However, in the subgroup
f patients aged over 70 years included in GISSI-3,
itrates administered within 24 hours of the onset of
yocardial infarction signiﬁcantly reduced cardiovascular
omplications [59].
They may be particularly useful in subgroups of ACS
atients with recurrent or persistent myocardial ischaemia
nd/or left ventricular insufﬁciency and/or exacerbations of
heir high blood pressure [5]. They may be used temporarily
t low doses to relieve pain, in the absence of hypotension
r right ventricular infarction and with close monitoring of
lood pressure and for the onset of headaches.
otassium channel agonists
o data are available in older adults with ACS. This treat-
ent may, however, be considered in the case of clinically
ersistent angina if blood pressure values allow after the
nstitution of the other pharmacological classes.
yocardial revascularization
oronary reperfusion for myocardial infarction in older
dults remains a controversial subject, mainly because of
he under-representation or even exclusion of patients aged
ver 75 years in large clinical trials [60—62].
ntravenous thrombolysis in myocardial
nfarction in older adults
everal studies and registries have underlined the increased
isk of haemorrhage with advancing age during the hospi-
al phase [63,64]. Nevertheless, thrombolysis signiﬁcantly
educes 1-year mortality in patients over 75 years of age
65,66].
The risk of cerebral haemorrhage is twice as high after
he age of 85 years but remains acceptable (approximately
%) [67]. Factors predisposing to bleeding are: age, presence
f comorbidities, malnutrition, severe arterial hypertension
nd brain trauma.
oronary angioplasty
he results of a recent meta-analysis of randomized trials
68] show that angioplasty in patients aged over 80 years
as a greater beneﬁt than thrombolysis, with, in particular, a
etter survival and a lower risk of stroke. These conclusions
re coherent with those of observational studies [69—72].
his management strategy avoids the risks of haemorrhage
ue to thrombolysis. However, in older adults, angioplasty
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is accompanied by a risk of more severe complications than
in younger individuals (deaths, renal insufﬁciency, vascular
complications) [73]. An evaluation of renal function before
and after angioplasty is essential. It is particularly important
to apply preventive measures with adequate hydration in the
case of renal insufﬁciency. The indications for angioplasty
during the acute phase in older adults must therefore be
taken into account:
• clinical severity (recurrence of pain, heart failure);
• severity of the ischaemia (anterior territory or extension
to the right ventricle, large rise in troponin);
• delay after the onset of signs (< 6 hours);
• physiological status (life expectancy, quality of life);
• presence of comorbidities (renal insufﬁciency, cognitive
disorders, dependence, etc.).
Coronary angioplasty with or without stent
implantation
No randomized study has compared angioplasty with or with-
out stenting in the very elderly subject with myocardial
infarction.
Revascularization in the case of cardiogenic shock
According to the SHOCK study, irrespective of the revas-
cularization strategy (angioplasty or bypass) a reduction in
mortality at six months is observed only in those aged under
75 years [74]. However, certain studies suggest a beneﬁt
on mortality after early revascularization in elderly patients
selected according to individual criteria [75—77]. Revascu-
larization, in this setting, can only be decided at the end of
an individual decision process.
Coronary artery bypass grafting
The perioperative morbidity and mortality of bypass grafting
increase in older adults more especially if they have unstable
angina or require emergency surgery [78,79].
Summary
Angioplasty may be considered to be the technique of choice
for emergency reperfusion. However, if this technique can-
not be used, thrombolysis has beneﬁts that should entail its
wider use when the patient’s physiological status permits.
Treatment of chronic coronary disease
Medication for chronic ischaemic heart disease in older
adults comprises two aspects:
• symptomatic treatments to reduce the frequency of
angina pain and improve tolerance to exercise: nitrates,
beta-blockers, calcium channel blockers, molsidomine,
nicorandil, trimetazidine and ivabradine;
• secondary preventive treatments to improve outcomes by
reducing morbidity and mortality: beta-blockers, aspirin,
clopidogrel, statins, ACE inhibitors and ARAs.Treatment of angina attacks
For exertional angina, sublingual nitrates remain the
basic treatment to relieve pain. The risk of orthostatic
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ypotension after nitrate administration is increased in
lder adults, especially in the presence of aortic steno-
is. They must be taken while seated. The elderly subject
ust receive advice about the factors precipitating angina
ttacks, how to take glyceryl trinitrate and the recom-
ended treatment for intractable pain. The patient and
is/her close relations must understand this information.
ymptomatic treatment of stable angina
ectoris
ew data are available in the literature about the antiang-
na efﬁcacy of the different therapeutic classes in older
dults. The conclusions of trials in the general population
ave therefore been extrapolated to the elderly [80].
eta-blockers
he use of beta-blockers is recommended in the absence
f contraindications. Beta-blockers reduce the frequency
f angina attacks and episodes of silent ischaemia [81,82].
heir dosage must be adjusted to maintain a resting
eart rate of about 60 beats per minute and reduce
he acceleration of heart rate during exercise [20,83].
heir administration should respect the precautions for use
escribed in the section on ACS. A beta-1 selective beta-
locker should be preferred in patients with chronic and
table lower-limb arterial disease or diabetes. It is recom-
ended not to suddenly discontinue beta-blocker treatment
n patients with angina because of the increased risk of
nfarction and sudden death [84].
alcium antagonists
alcium channel blockers, indicated in stable chronic
ngina, have a similar antiangina efﬁcacy as beta-blockers
85]. The use of the rate-limiting calcium antagonists (dil-
iazem, verapamil) in older adults is contraindicated in the
ase of decompensated heart failure, severe conduction dis-
rders and beta-blocker administration.
ong-acting nitrates
ong-acting nitrates reduce the frequency and severity of
ngina attacks. No placebo-controlled study has been per-
ormed showing that nitrates have a beneﬁt on morbidity
nd mortality. They reduce the frequency and severity of
ngina attacks, but in older adults they are also one of
he main therapeutic classes responsible for orthostatic
ypotension. They may be used in the case of contraindi-
ation or poor tolerability of beta-blockers and calcium
ntagonists [82]. Tight aortic stenosis and obstructive car-
iomyopathy are contraindications to the use of nitrates.
ther antiangina agents: molsidomine,
icorandil, trimetazidine, ivabradineolsidomine is a nitric-oxide donor with similar effects to
itrates. Nicorandil is a potassium channel activator with
vasodilator effect with similar effects to nitrates. The
ONA [86] study showed a beneﬁt for hospital readmissions
or angina, but did not include very elderly subjects. These
8t
t
t
b
t
r
h
m
a
S
A
e
a
o
a
A
T
i
d
i
t
t
l
m
c
c
t
e
o
[
B
T
r
t
i
p
v
r
v
r
i
a
p
t
[
e
y
e
i
l
d
i
S
S
o
p
d
p
n
d
m
d
r
d
r
m
i
p
A
A
d
6
p
e
o
d
m
b
p
L
S
c
i
b
p
t
P
I
s
c
l
c
a
m
r
t
w
r
M36
wo products may be used as an alternative to nitrates when
hese are poorly tolerated.
Trimetazidine is a metabolic antiangina drug that inhibits
he beta-oxidation of fatty acids by mitochondria. It has not
een shown to have an effect on prognosis [87].
The role of new heart-rate-lowering antiangina agents
hat inhibit the I(f) current, such as ivabradine, is not cur-
ently codiﬁed in very elderly subjects as no speciﬁc study
as been performed in this population. Symptomatic treat-
ent must be reassessed regularly and may be reduced if
ngina attacks become rare.
econdary prevention
s in younger patients, the secondary prevention of coronary
vents in older adults is based on the use of antithrombotic
gents, beta-blockers, ACE inhibitors/ARAs and statins, and
n the control of blood pressure, in combination with diet
nd lifestyle measures.
ntiplatelet therapy
reatment with platelet-aggregation inhibitors is indicated
n older adults for the secondary prevention of myocar-
ial infarction. Treatment must be continued indeﬁnitely
n the absence of haemorrhagic complications. The inhibi-
ion of platelet aggregation by aspirin effectively prevents
he recurrence of myocardial infarction and cardiovascu-
ar mortality. The Antiplatelet Trialists Collaboration [88]
eta-analysis showed a 27% reduction in cardiovascular
omplications (infarction, stroke and death from vascular
auses) with aspirin. This beneﬁt was observed irrespec-
ive of age group (> or < 65 years). Clopidogrel has proven
fﬁcacy for the prophylaxis of myocardial infarction in the
ver 65 subgroup of patients at high cardiovascular risk
89].
eta-blockers, ACE inhibitors and ARAs
he dosages of beta-blockers and inhibitors of the
enin-angiotensin system must be adjusted according to
heir safety, and treatment continued indeﬁnitely. Mon-
toring procedures are the same as during the acute
hase.
Beta-blockers are recommended for the secondary pre-
ention of myocardial infarction. Their administration
educes the risk of death in older adults who have sur-
ived myocardial infarction [90]. ACE inhibitors are also
ecommended for the secondary prevention of myocardial
nfarction in the elderly provided that they are well toler-
ted (in particular with respect to blood pressure and renal
arameters). They are effective after myocardial infarc-
ion, with [52,91,92] or without left ventricular dysfunction
93—96] to reduce the risk of mortality and cardiovascular
vents. This beneﬁt is similar whatever the age (< or > 65
ears [82,85]), although these studies did not include very
lderly patients.ARAs had a similar beneﬁt to that observed with ACE
nhibitors in post-infarction complicated by heart failure or
eft ventricular dysfunction and in patients with coronary
isease [55,97]. They may therefore be used in patients
ntolerant to ACE inhibitors.
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tatins
tatins are recommended for the secondary prevention
f myocardial infarction in older adults. They effectively
revent coronary events in elderly subjects at high car-
iovascular risk. The PROSPER study [98], which included
atients aged 70 to 82 years, showed that pravastatin sig-
iﬁcantly reduced the risk of death from coronary artery
isease. In the Heart Protection Study [99], which included
ore than 5000 patients over 75 years of age with arterial
isease, cerebrovascular disease or diabetes, simvastatin
educed the incidence of a ﬁrst non-fatal episode of myocar-
ial infarction or death from coronary disease. The risk
eduction was similar whatever the age. Lastly, a recent
eta-analysis showed a 22% reduction in 5-year mortality
n patients over 65 years receiving statins for secondary
revention [100].
ntihypertensive medication
ntihypertensive medications effectively reduce the inci-
ence of myocardial infarction in hypertensive subjects aged
0 to 80 years, with a risk reduction of 20—30% [101]. In
atients aged over 80 years, the HYVET study showed a ben-
ﬁt of treatment with thiazide diuretic (indapamide) with
r without an ACE inhibitor, with a 34% reduction in car-
iovascular events [102]. In this study, the 28% reduction in
yocardial infarction observed with treatment was found to
e non-signiﬁcant, possibly because of the lack of statistical
ower after premature discontinuation of the study.
ifestyle changes
moking cessation has a positive impact on the outcome of
oronary artery disease, including in elderly subjects. Smok-
ng cessation after myocardial infarction reduces mortality
y 25—50% [103], regardless of age. Smoking cessation is
ossible in older adults and is achieved at rates equivalent
o or higher than those observed in younger subjects.
hysical exercise and rehabilitation
n the general population, controlled trials have demon-
trated the beneﬁt of rehabilitation in terms of functional
apacities, mortality [104], reduction in atherosclerosis
esions [105] and in the number of hospital admissions for a
oronary event [106]. The impact of rehabilitation in older
dults was not speciﬁcally evaluated.
Rehabilitation also leads to an improvement in perfor-
ance of the ADL [107]. Besides aerobic rehabilitation,
esistance-training techniques (anaerobic) are effective in
he elderly [108—110]. Exercises performed at home are as
ell tolerated and as effective as exercises performed in
ehabilitation centres with medical monitoring [111].
anagement of excess body weightbesity is a traditional risk factor for coronary artery dis-
ase, including in the elderly [112,113]. Body mass index
hould be calculated in all coronary patients [114]. How-
ver, in the case of malnutrition, body mass index [115]
annot be used to recognize sarcopenic obesity (obesity with
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weight loss due to loss of muscle mass), which is particularly
frequent in older subjects.
As no interventional study has yet been performed, the
dietetic procedures required to reduce cardiovascular risk
in overweight older adults do not form the subject of a
consensus. In overweight, elderly coronary patients a small
reduction (500 to 700 kcal/j) in energy intake may be pro-
posed while maintaining a daily protein intake of 1 g/kg
per day in order to achieve a weight loss of 8—10% in six
months [116]. Conversely, too great a weight loss in an
elderly patient may have a negative effect by decreasing the
muscle mass and protein reserve. Regular physical activity
may increase weight loss without leading to muscle loss and
should be widely recommended in elderly subjects.
Myocardial revascularization
The type of myocardial revascularization (angioplasty or
surgery) performed in older adults depends on clinical
criteria (comorbidities, clinical severity) and paraclini-
cal parameters (documented myocardial ischaemia, left
ventricular function, angiographic appearance of coronary
lesions). A case-by-case evaluation is necessary in these
patients in order to evaluate the beneﬁt-risk ratio.
Coronary angioplasty
Angioplasty allows rapid treatment of coronary lesions com-
pared with surgery, which generally requires extracorporeal
circulation. Long hospital stays generating complications
speciﬁc to this type of patient are therefore avoided.
However, in older adults the coronary arteries needing
revascularization are often the site of particularly complex
lesions (extensive, diffuse, calciﬁed lesions with frequent
stenosis of the left main trunk and chronic coronary occlu-
sions) [117].
Primary success rates vary between 80 and 96%, but
revascularization is generally incomplete in patients aged
over 75 years [118], with a history of infarction [119], with
calciﬁed total or sub-total coronary occlusion [120], or in
the case of involvement of the circumﬂex artery [121].
The technical difﬁculties of PTCA place elderly
patients in a high-risk group for per- and post-procedure
complications [122—125].
Although the in-hospital complication rates and mortality
are low, they are slightly higher than those of a younger pop-
ulation (2—3%). After 65 years of age, in-hospital mortality
is independently associated with a left ventricular ejec-
tion fraction less than 40%, the existence of triple-vessel
lesions and with female gender [126]. Medium-term mor-
tality after successful PTCA is not increased in older adults
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127]. Compared with the medical strategy, PTCA has no
eneﬁt on mortality or on the recurrence of major cardio-
ascular events, but improves quality of life [128,129].
The indications for stenting in older adults are the same
s in younger patients. The beneﬁt compared with PTCA
lone is not documented in patients aged over 80 years.
he risk of bleeding induced by dual antiplatelet therapy
hould be carefully assessed before implanting a drug-
luting stent.
oronary artery bypass grafting
he beneﬁt of surgery on survival has been demonstrated
n older adults but few studies have included patients aged
ver 80 years [130]. Coronary artery bypass grafting has a
igh risk of complications (stroke, cognitive impairment,
leeding, respiratory decompensation), of approximately
0% in octogenarians [78,131].
The main predictive factors of mortality are an elderly
ge, female gender, resting angina, diabetes, left ventric-
lar ejection fraction less than 40%, heart failure, renal
nsufﬁciency and emergency surgery [132]. In this setting,
he appropriateness of surgical revascularization should be
arefully considered by taking into account in particular the
isk of deterioration of cognitive function observed after a
urgical procedure.
The use of scores, such as EuroSCORE [133,134], may help
o evaluate the risk of postoperative mortality, taking into
ccount patient-related parameters (age, comorbidities),
ardiopathy (left ventricular ejection fraction, unstable
ngina) and the surgical procedure (emergency surgery,
oncomitant non-coronary surgery, surgery of the chest
orta, septal rupture).
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seful method for the evaluation of the cognitive status of
atients by the clinician. Consensual French version. Presse
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ppendix 2. Simpliﬁed IADL Scale (PAQUID Study)
eference: Barberger-Gateau P, Dartigues JF, Letenneur L. Four Instrumental Activities of Daily Living Score as a predictor
f one-year incident dementia. Age Ageing 1993;22:457—63.
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Appendix 3. Katz ADL Scale
Reference: Katz A, Ford AB, Moskowitz RW et al. Studies
of illness in the aged. The index of ADL: a standardized
measure of biological and psychosocial function. J Am Med
Assoc 1963;185:914—9
Appendix 4. Mini GDS (Geriatric
Depression Scale), mood assessment
Reference: Clément J-P, Nassif RF, Leger JM, Marchan F.
Mise au point et contribution à la validation d’une version
franc¸aise brève de la Geriatric Depression Scale de Yesav-
age. L’Encéphale 1997;XXIII:91—9.
Ask the patient to answer the questions by saying how
he/she has felt during the last week and not during his life
or at the present time.
1. Do you often feel discouraged
and sad?
yes = 1, no = 02. Do you feel that your life is
empty?
yes = 1, no = 0
3. Are you happy most of the time? yes = 0, no = 1
4. Do you have the impression that
your situation is desperate?
yes = 1, no = 0er adults 841
Score
If total score equal or greater than 1, strong probability
f depression
If total score = 0, strong probability of no depression
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